Is Europe doing enough to prepare for bird flu risks to humans?
As bird flu spreads across Europe and jumps to more animal species, health experts warn that gaps in surveillance and preparedness could leave the region vulnerable to future threats to human health.
Avian influenza has been spreading at elevated levels worldwide over the past five years, including in wild and farm birds in the European Union.
Hungary has reported the most outbreaks since last autumn, followed by Germany, the Netherlands, and poultry giant Poland.
But in recent years, bird flu has also spread to mink, cats, a captive bear, and other mammals, raising the risk that the virus will eventually reach people.
Tens of millions of birds and other animals have been culled to keep that from happening, but gaps in surveillance systems increase the likelihood that the virus could circulate undetected and become harder to control.
Since 2003, about half of the nearly 1,000 people infected with H5N1 bird flu globally have died.
Now, EU health officials say public health risks remain low, and there is no evidence of human-to-human transmission.
But preparations are already underway: the European Commission recently clinched a deal to secure more than 27 million influenza vaccines in case of a pandemic.
Officials are also eyeing an outbreak among dairy cows in the United States – which has spread to people, infecting 70 and killing one – as a reminder to monitor animals beyond birds and mink, which are more prone to infection.
"It's not a time to really sit back and relax and say, 'oh well, this is just business as usual,'" Marion Koopmans, who directs the centre of excellence at the Global Virus Network and leads the viroscience department at Erasmus Medical Centre in the Netherlands, told Euronews Health.
"It has really changed compared with just a few years ago," she added. "It's not a good situation to have".
EU countries actively monitor wild birds and poultry for avian influenza. When they find infections, they must take steps to stamp out the virus, such as culling birds and imposing farm restrictions.
Now, with the US cattle outbreak in mind, the European Food Safety Authority (EFSA) is working with member states to boost surveillance in cows and other mammals, according to Alessandro Broglia, one of the agency's senior scientists.
"There is a kind of reactivity and enhanced preparedness in Europe, also to prevent the infection in cattle and other farm animals," Broglia told Euronews Health.
Vaccination is also playing a bigger role. In 2023, France began immunising birds, a move it says has helped its poultry industry recover after outbreaks ravaged its farms and annihilated tens of millions of birds.
And last summer, Finland became the first EU country to offer bird flu vaccines to people, doling out jabs to 10,000 workers who were at higher risk of infection.
Even so, EU audits have identified gaps in these systems that could be just large enough for the virus to slip through undetected.
Over the past two years, they have found delays in setting up restriction zones to prevent the virus from spreading in Poland; "limited effectiveness" in Portugal's early warning system for poultry infections; shortcomings in investigations of suspected cases in Spain; and poor risk assessment, a lack of surveillance, and inadequately trained staff in Hungary that constitute "crucial weaknesses" that have not been rectified since the country was last audited in 2020.
A Commission spokesperson told Euronews Health that Spain and Portugal have taken steps to fix these issues, but that it is 'seeking additional commitments' from Hungary and Poland, which suspended poultry exports last month due to outbreaks.
Alexandre Fediaevsky, acting head of preparedness and resilience at the World Organisation for Animal Health (WOAH), said that 'in all countries, Europe included, there is still some room for improving biosecurity and early warning systems'.
But there has been some resistance from some farmers and poultry industry groups, who fear new rules and restrictions could threaten their businesses.
"We need to have some strategic dialogue with the industry," Fediaevsky told Euronews Health, but "it will be a long process to really transform the production systems".
The EU and the US are not the only places grappling with elevated bird flu risks. Last week, the Commission said poultry and meat imports from Brazil had been halted after the country confirmed its first bird flu outbreak on a farm.
For now, bird flu appears to pose a greater risk to the EU's food supply than to public health. However, Koopmans warned that without stronger measures to curb the virus' spread among birds, the bloc could be caught off guard if human infections begin to emerge.
"Let's also not become negligent," she said, "because this is how these viruses eventually trigger pandemics".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
3 days ago
- Euronews
Data-sharing gives rare disease patients another chance at diagnosis
Arne Cavents was four years old when he was misdiagnosed. Growing up in a small city in Belgium, Cavents knew he was different from other children. He'd had surgery to correct his inward-turning legs, and had difficulty tying his shoes and riding a bicycle. Due to his symptoms, he was believed to have Charcot-Marie-Tooth disease (CMT), a progressive hereditary condition that causes muscle weakness in the feet, ankles, legs, and hands. His mother, sister, and grandmother suffered the same issues. It wasn't until 2017, when Cavents and his wife started thinking about having children, that he decided to get genetic testing to confirm the diagnosis. But five years and three hospital visits later, the tests had only ruled out CMT – until he received a call in 2022 from a doctor in Antwerp who had detected an unusual mutation in one of his genes. Cavents was eventually diagnosed with distal myopathy with early childhood onset, a rare condition that, like CMT, causes weakness in the feet. His doctor estimates it affects one in one million people. 'Finally, we know what is going on,' Cavents, a 32-year-old health insurance agent, told Euronews Health. He said the diagnosis was 'a great relief' after years of 'uncertainty, sadness, hope, [and] disappointment'. Cavents is one of hundreds of patients with previously unknown genetic conditions who got answers as a result of a European programme to give them a second chance at diagnosis. By definition, these conditions affect fewer than five people per 10,000, and about 80 per cent have genetic origins. On average, patients wait 4.7 years before they are diagnosed, with younger people facing longer delays that can make it harder to find the right treatment, according to a 2022 survey of more than 10,000 rare disease patients across Europe. Diagnosis 'is really the first step,' Roseline Favresse, head of research policy and initiatives at the advocacy group European Organisation for Rare Diseases, told Euronews Health. As part of a study published in the journal Nature Medicine this year, researchers from 37 medical centres across Europe pooled their data and reexamined the records of about 6,500 rare disease patients who did not have a genetic confirmation of their diagnosis, as well as 3,200 relatives. This data-sharing partnership, known as Solve-RD, allowed researchers to analyse more recent studies on gene mutations, use cutting-edge technology to identify potential variants, and consult experts in other countries – a key component because these conditions are so rare that many diagnosticians lack expertise in any one particular disease. 'By having novel software tools to mine the data, with existing data you can make a new genetic diagnosis,' said Richarda de Voer, an associate professor of cancer genomics at Radboud University Medical Centre in the Netherlands, who worked with Solve-RD to diagnose rare hereditary cancers. As part of the Solve-RD programme, more than 500 people were diagnosed with rare neurological disorders, severe intellectual disabilities, muscle diseases, hereditary gastrointestinal cancer, and other conditions. For about 15 per cent of them, diagnosis led directly to new treatment options or other medical support. For the rest, it offered clarity and hope that new treatments could become available in the future. 'These disorders are rare, they are genetic, and in the past, we would say they are not curable,' Dr Jonathan De Winter, a rare disease researcher at the University of Antwerp and Cavents' doctor, told Euronews Health. 'But that's really changing in the past years,' he added. For Cavents, his diagnosis opened the door to fatherhood after years spent worrying he could pass his condition on to his children. He and his wife will now have the option to monitor for the genetic variant through prenatal diagnostics or during in vitro fertilisation (IVF), in which embryos would be tested for the mutation before being implanted into his wife's uterus. Despite the lack of treatment options for Cavents at present, his diagnosis has been so life-changing that he and his wife sometimes joke about naming their future child after De Winter. 'It's been a long road. In the end, it is a positive outcome for me,' he said. The Solve-RD programme ended in 2024, but its early findings are central to a new international project that aims to improve prevention, diagnosis, and treatment for Europe's 30 million rare disease patients. Through the new project, known as the European Rare Disease Research Alliance (ERDERA), researchers are working with bigger genetic datasets and incorporating more advanced genome sequencing technology that should help them detect complex mutations. 'We use the lessons learned from Solve-RD for ERDERA,' Alexander Hoischen, a geneticist and professor at Radboud University who co-led the Solve-RD project, told Euronews Health. 'We are now already more efficient in making diagnoses,' he added. As a result, clinicians should be able to share some potential new insights with patients within the next year, according to Holm Graessner, a rare disease researcher in Germany who worked with Solve-RD and now co-leads ERDERA's clinical research network. 'We now have the chance to… scale it up, to further develop it, and to include further countries,' Graessner told Euronews Health. As researchers take those steps, patient advocates want the programme to move beyond academic settings to make genetic reanalysis available in all clinics that treat rare disease patients. 'What we hope to see is a significant increase in the percentage of cases solved after reanalysis,' Favresse said, as well as 'equal opportunities for everyone to benefit from a second chance at being diagnosed'. A new artificial intelligence (AI) tool could boost health outcomes for some men with prostate cancer by identifying whether they would benefit from a promising treatment. The drug abiraterone works by blocking testosterone production throughout the body, including in the tumour. It's been shown to slash the risk of death by nearly half for about one in four men with prostate cancer – but it can be costly and have side effects, making health authorities wary of prescribing it too readily. That means getting abiraterone to the right patients at the right time could help improve their prognosis, while also avoiding over-treating patients who might not benefit from the drug, according to the study led by UK institutions. 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy,' Nick James, the study's co-lead and a professor of prostate and bladder cancer research at the UK's Institute of Cancer Research, said in a statement. The findings were presented this week at the American Society of Clinical Oncology's annual meeting in Chicago. Scientists used AI to study images of tumour samples and identify biomarkers that could have otherwise gone undetected, and then applied the test to biopsy images from more than 1,000 men who had participated in another clinical trial on prostate cancer treatments. Among patients with biomarker-positive tumours, abiraterone slashed the risk of death from 17 per cent to 9 per cent within five years. For those with biomarker-negative tumours, abiraterone did not significantly reduce their mortality risks – meaning these patients should receive standard treatment, the study concluded. Researchers noted that abiraterone can cause side effects such as high blood pressure, liver problems, and diabetes, meaning the AI tool could help direct prostate cancer patients to the best treatment for them. 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over treatment whilst maximising the chance of cure,' Gert Attard, the study's co-lead and a professor of medical oncology at the University College London Cancer Institute, said in a statement. In the United Kingdom, abiraterone has been approved in Scotland and Wales to treat newly-diagnosed, high-risk prostate cancer that has not yet spread, but in England, it is only available through the National Health Service (NHS) for men whose cancer has metastasised. The researchers called on the NHS to reassess this decision, saying 8,400 men per year could potentially benefit from the drug. 'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free,' James said. Prostate cancer is one of the most common forms of cancer for men, with nearly 336,000 new cases diagnosed every year in the European Union.
Euronews
4 days ago
- Euronews
Spain plans to extend smoking ban to bar and restaurant terraces
Spain is moving forward with plans to extend smoking bans to public spaces, including restaurant terraces and outdoor areas in bars, the southern European country's health minister announced on Thursday. More than a year after Spain's left-wing government coalition passed its anti-smoking plan, Spain's Health Minister Monica García announced that "a concrete draft of the bill" had been completed in an interview with Cadena SER radio. García added that the prospective ban would also apply to electronic cigarettes and heated tobacco devices, and not just traditional tobacco. García said she hoped that the ban — which must still be reviewed by the government's council of ministers, as well as the Spanish parliament's lower house — would place Spain "at the forefront of the fight against smoking". School playgrounds, university campuses, company vehicles, as well as outdoor festive events and public transport shelters, are among the other places where the ban would be imposed. As part of its anti-smoking plan, the Spanish government has also been working on a range of measures, including boosting resources available to individuals who wish to quit smoking, as well as introducing a tax hike on tobacco and similar products. Spain has joined other European countries which have considered introducing similar laws following a recommendation by the European Commission to extend smoking bans to further public areas and include electronic cigarettes. In September 2024, French authorities announced they were working on a proposal to ban smoking at outdoor restaurant and café terraces. Italy has mulled a similar law since 2023, but no progress has been made on a nationwide rule, bar a ban in Milan and a proposed temporary testing period in Rome's 1st municipality, which encompasses most of its historic centre. Outside of the EU, UK Prime Minister Keir Starmer said in August 2024 that the government was looking into more rigid rules on outdoor smoking at pubs and restaurants, in a bid to lower preventable deaths linked to tobacco use. Opponents of the legislation argue that it would be too excessive and negatively impact small businesses, which could lose customers if the ban were extended to outdoor areas.
LeMonde
4 days ago
- LeMonde
Trump administration cancels contract with Moderna to develop bird flu vaccine
US President Donald Trump's administration on Wednesday, May 28, canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said. It marked the latest move against vaccines by Health Secretary Robert F. Kennedy Jr, who has spent decades promoting misinformation about immunization. The contract, announced on January 17 – three days before Trump took office – was for an mRNA vaccine targeting the H5N1 influenza strain, which has been circulating in birds and cattle. Experts have warned the virus could jump to humans and spark a pandemic. American pharmaceutical and biotechnology company Moderna disclosed the news as it announced positive results from an early-stage clinical trial of 300 people designed to test safety and immune response. "While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program," said CEO Stephane Bancel in a statement. "These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats." The statement added Moderna would "explore alternatives" for funding the development and manufacturing of the vaccine. Dr. Ashish Jha, a public health expert who served as former president Joe Biden's Covid-19 response coordinator, reacted with dismay. "The attack on mRNA vaccines is beyond absurd," he posted on X. "It was President Trump's Operation Warp Speed that gave us mRNA vaccines."
